Precision BioSciences (NASDAQ:DTIL) PT Raised to $60.00 at HC Wainwright

Precision BioSciences (NASDAQ:DTIL) had its price target raised by HC Wainwright to $60.00 in a research note issued on Thursday, March 28th, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 288.60% from the stock’s previous close. HC Wainwright also issued estimates for Precision BioSciences’ Q1 2025 earnings at ($0.85) EPS, Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.81) EPS and Q4 2025 earnings at ($0.68) EPS.

Precision BioSciences Trading Up 8.7 %

Shares of NASDAQ:DTIL opened at $15.44 on Thursday. Precision BioSciences has a 12 month low of $8.25 and a 12 month high of $28.44. The firm’s 50-day moving average is $12.56 and its 200 day moving average is $11.60.

Insider Buying and Selling at Precision BioSciences

In other news, CEO Michael Amoroso sold 4,579 shares of the stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $10.80, for a total value of $49,453.20. Following the sale, the chief executive officer now owns 11,881 shares in the company, valued at $128,314.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last quarter, insiders have sold 6,005 shares of company stock worth $64,854. 5.10% of the stock is owned by corporate insiders.

Institutional Trading of Precision BioSciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in Precision BioSciences by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 4,754,776 shares of the company’s stock valued at $1,735,000 after buying an additional 61,700 shares during the period. BlackRock Inc. grew its position in Precision BioSciences by 4.0% during the first quarter. BlackRock Inc. now owns 4,566,690 shares of the company’s stock valued at $14,067,000 after buying an additional 175,176 shares during the period. Acadian Asset Management LLC grew its position in Precision BioSciences by 8.3% during the third quarter. Acadian Asset Management LLC now owns 3,148,243 shares of the company’s stock valued at $1,073,000 after buying an additional 242,425 shares during the period. Renaissance Technologies LLC grew its position in Precision BioSciences by 139.6% during the third quarter. Renaissance Technologies LLC now owns 2,172,666 shares of the company’s stock valued at $2,824,000 after buying an additional 1,265,877 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in Precision BioSciences by 32.6% during the first quarter. JPMorgan Chase & Co. now owns 2,107,506 shares of the company’s stock valued at $1,588,000 after purchasing an additional 517,702 shares in the last quarter. Institutional investors and hedge funds own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences, Inc, a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders.